Drug class in one race
Activin/myostatin type II receptor drugs for Obesity
4 tracked Activin/myostatin type II receptor drugs in the Obesity race. The class explanation lives on the Activin/myostatin type II receptor page; the full indication pipeline across every mechanism is on the Obesity page.
3 Phase 21 Phase 1
Head-to-head evidence: apitegromab vs LAE102/LAE103 · bimagrumab vs LAE102/LAE103 · apitegromab vs bimagrumab · apitegromab vs taldefgrobep alfa · bimagrumab vs taldefgrobep alfa